Bioequivalence Study of Paricalcitol Capsules, 4 mcg Under Fasting Conditions

An Open-label, Balanced, Randomized, Two-treatment, Two-sequence, Two-period, Single-dose, Crossover Oral Bioequivalence Study of Paricalcitol Capsules 4 mcg of Dr. Reddy's Laboratories Limited and Zemplar Capsules, 4 mcg of Abbott Laboratories, USA in Healthy, Adult, Human Subjects Under Fasting Conditions.

An open-label, balanced, randomized, two-treatment, two-sequence, two-period, single-dose, crossover oral bioequivalence study in healthy subjects under fasting conditions.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Drug: Paricalcitol Capsules, 4 mcg

Detailed Description

An open-label, balanced, randomized, two-treatment, two-sequence, two-period, single-dose, crossover oral bioequivalence study of Paricalcitol Capsules 4 mcg of Dr. Reddy's Laboratories Limited and Zemplar® Capsules 4 mcg of Abbott Laboratories, USA in healthy, adult, human subjects under fasting conditions.

• Study Type: Interventional
• Enrollment (Actual): 69
• Phase: Phase 1

Contacts and Locations

Study Locations

• India
  • Gujarat
    • Ahmedabad, Gujarat, India, 3 80 061
      • Lambda Therapeutic Research Ltd

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 55 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Healthy, adult, human volunteers between 18 and 55 years of age (both inclusive) living in and around Ahmedabad city of western part of India.
• Having a Body Mass Index (BMI) between 18.5 and 24.9 (both inclusive), calculated as weight in kg/height in m2.
• Have no significant diseases or clinically significant abnormal findings during screening, medical history, clinical examination, laboratory evaluations, 12- lead ECG and X-ray chest (postero-anterior view) recordings.
• Volunteers who have normal calcium, phosphorous status and no hypertensive status in order to avoid effect on vitamin D concentration in blood.
• Able to comply with the study procedures, in the opinion of the Principal investigator.
• Able to give voluntary informed consent for participation in the trial.

In case of female subjects*:

• Surgically sterilized at least 6 months prior to study participation; Or
• If of child bearing potential is willing to use a suitable and effective double barrier contraceptive method or intra uterine device during the study.
• Urine pregnancy test (for female subjects*) must be negative at the time of screening. *No female subjects were enrolled in the study.

Exclusion Criteria:

• Known hypersensitivity or idiosyncratic reaction to Paricalcitol or to any of its excipients or any drug or any substance.
• History or presence of any disease or condition which might compromise the haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal or any other body system.
• Ingestion or Use of any medication at any time in 14 days prior to dosing. In any such case subject selection will be at the discretion of the Principal Investigator.
• Any history or presence of asthma (including aspirin induced asthma) or nasal polyp or NSAID induced urticaria.
• Consumption of Grapefruits or its products within a period of 48 hours prior to check-in.
• A recent history of harmful use of alcohol(less than 2 years), i.e. alcohol consumption of more than 14 standard drinks per week for men and more than 7 standard drinks per week for women (A standard drink is defined as 360 ml of beer or 150 ml of wine or 45 ml of 40% distilled spirits, such as rum, whisky, brandy etc). " or consumption of alcohol or alcoholic products within 48 hous prior to check-in.
• Smokers, who smoke 10 or more than 10 cigarettes / day or inability to abstain from smoking during the study.
• The presence of clinically significant abnormal laboratory values during screening.
• Use of any recreational drugs or history of drug addiction or testing positive in pre-study drug scans.
• History or presence of psychiatric disorders.
• A history of difficulty with donating blood.
• Donation of blood (1 unit or 350 mL) or receipt of an investigational medicinal product or participation in a drug research study within a period of 90 days prior to the first dose of study medication. Elimination half-life of the study drug should be taken into consideration for inclusion of the subject in the study. Note: In case the blood loss is ≤ 200 mL, subject may be enrolled 60 days after blood donation or last sample of the previous study.
• A positive hepatitis screen including hepatitis B surface antigen and anti- HCV antibodies.
• A positive test result for anti-HIV antibody.
• An unusual diet, for whatever reason (e.g. low-sodium), for four weeks prior to receiving the study drug and throughout the subjects' participation in the study. In any such case subject selection will be at the discretion of the Principal Investigator. Nursing mothers (females)*. *No female subjects were enrolled in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Paricalcitol Capsules, 4 mcg; Paricalcitol Capsules, 4 mcg of Dr. Reddy's Laboratories Limited	Drug: Paricalcitol Capsules, 4 mcg; Paricalcitol Capsules, 4 mcg of Dr. Reddy's Laboratories Limited; Other Names: Zemplar
Experimental: Zemplar Capsules, 4 mcg; Zemplar Capsules, 4 mcg of Abott Laboratories USA	Drug: Paricalcitol Capsules, 4 mcg; Paricalcitol Capsules, 4 mcg of Dr. Reddy's Laboratories Limited; Other Names: Zemplar

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Area under curve	0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 3.5, 4.0, 6.0, 8.0, 10.0, 12.0, 16.0, 24.0, 36.0, 48.0 and 60.0 hours post-dose

Collaborators and Investigators

• Sponsor: Dr. Reddy's Laboratories Limited
• Investigators: Principal Investigator: Dr. Pankaj Kumar Jha, MD, Lambda Therapeutic Research Limited

Study record dates

Study Major Dates

• Study Start: November 1, 2010
• Primary Completion (Actual): December 1, 2010
• Study Completion (Actual): February 1, 2011

Study Registration Dates

• First Submitted: December 18, 2014
• First Submitted That Met QC Criteria: December 18, 2014
• First Posted (Estimate): December 23, 2014

Study Record Updates

• Last Update Posted (Estimate): December 23, 2014
• Last Update Submitted That Met QC Criteria: December 18, 2014
• Last Verified: December 1, 2014

More Information

Terms related to this study

• Other Study ID Numbers: 280-01